Gsk (GSK) Capital Expenditures (2009 - 2026)
Gsk (GSK) posted quarterly Capital Expenditures of -$440.1 million for Q2 2026, down 28.86% year-over-year from -$618.6 million in Q2 2025, and down 47.7% quarter-over-quarter from -$297.9 million in Q1 2026.
Gsk (GSK) Capital Expenditures (2009 - 2026) Analysis & Trends
Gsk's Capital Expenditures history runs 18 years deep, the most recent figure standing at -$440.1 million for Q2 2026.
- In Q2 2026, Capital Expenditures fell 28.86% year-over-year to -$440.1 million; the TTM figure through Jun 2026 stood at -$3.0 billion (down 5.56% YoY), while the FY2025 annual figure was $1.8 billion, down 0.61% from the prior year.
- Capital Expenditures for Q2 2026 stood at -$440.1 million, down from -$297.9 million in the prior quarter.
- The five-year high for Capital Expenditures was -$259.0 million in Q1 2022, with the low at -$1.8 billion in Q4 2024.
- The 5-year median for Capital Expenditures is -$374.6 million (2023), against an average of -$629.3 million.
- The sharpest annual moves came in 2025 and 2026: Capital Expenditures advanced 16.73% in 2025, then retreated 28.86% in 2026.
- Gsk's Capital Expenditures stood at -$1.3 billion in 2022, then declined by 21.65% to -$1.6 billion in 2023, then slipped by 10.1% to -$1.8 billion in 2024, then rose by 0.14% to -$1.8 billion in 2025, then soared by 75.46% to -$440.1 million in 2026.
- Business Quant data shows GSK's Capital Expenditures at -$440.1 million in Q2 2026, -$297.9 million in Q1 2026, and -$1.8 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.32 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 322.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 893.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 321.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 513.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 140.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 533.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -440.07 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -440.07 Mn |
| Jun 30, 2026 | -440.07 Mn |
| Mar 31, 2026 | -297.95 Mn |
| Mar 31, 2026 | -297.95 Mn |
| Dec 31, 2025 | -1.79 Bn |
| Dec 31, 2025 | -1.79 Bn |
| Sep 30, 2025 | -419.65 Mn |
| Sep 30, 2025 | -419.65 Mn |
| Jun 30, 2025 | -341.52 Mn |
| Jun 30, 2025 | -341.52 Mn |
| Mar 31, 2025 | -261.98 Mn |
| Mar 31, 2025 | -261.98 Mn |
| Dec 31, 2024 | -1.80 Bn |
| Dec 31, 2024 | -1.80 Bn |
| Sep 30, 2024 | -396.29 Mn |
| Sep 30, 2024 | -396.29 Mn |
| Jun 30, 2024 | -381.19 Mn |
| Jun 30, 2024 | -381.19 Mn |
| Mar 31, 2024 | -314.59 Mn |
| Mar 31, 2024 | -314.59 Mn |